DTP Emerging as Practical Patient-Centricity
This white paper podcast is part of DIA’s White Paper Library
One of the most basic aspects of critical trials, helping patients maintain their therapeutic regimens, was greatly impacted by the travel and social restrictions of COVID-19: Delivering and distributing investigational drugs to maintain the trial while keeping patients and site employees safe in the process. “The pandemic forced everyone to think differently. We were all running a crisis and the main challenge was how to keep patients under treatment. Direct to patient (DTP) means shipping the drug to the patient home, or to patient location according to his choice, instead of having the patient coming to the clinical site. That allows patients to stay at home. There is no need to go anywhere and jeopardize their immune system in a pandemic,” explains Neta Bendelac, Senior Director of Strategy, 4G Clinical. “Flexibility is the name of the game here. 4G’s model for DTP allows different configurations of the solution. A study may want to allow DTP, but a patient may prefer not to have DTP and they would prefer to come to the site. Our RTSM (randomization and trial supply management) can be set up to enable each patient to choose between DTP and the traditional settings. That is being patient-centric.”
 |
|
Neta Bendelac
Senior Director of Strategy
|
Download Now!
INTERESTED IN PUBLISHING?
For more information on publishing your White Paper with DIA, including schedule and pricing, please contact Heej Ko at [email protected].
For more information on publishing your White Paper with DIA, including schedule and pricing, please contact Heej Ko at [email protected].